Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

654 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway.
Levallet G, Bergot E, Antoine M, Creveuil C, Santos AO, Beau-Faller M, de Fraipont F, Brambilla E, Levallet J, Morin F, Westeel V, Wislez M, Quoix E, Debieuvre D, Dubois F, Rouquette I, Pujol JL, Moro-Sibilot D, Camonis J, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique (IFCT). Levallet G, et al. Among authors: dubois f. Mol Cancer Ther. 2012 May;11(5):1203-13. doi: 10.1158/1535-7163.MCT-11-0899. Epub 2012 Mar 12. Mol Cancer Ther. 2012. PMID: 22411898 Clinical Trial.
MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.
Levallet G, Dubois F, Fouret P, Antoine M, Brosseau S, Bergot E, Beau-Faller M, Gounant V, Brambilla E, Debieuvre D, Molinier O, Galateau-Sallé F, Mazieres J, Quoix E, Pujol JL, Moro-Sibilot D, Langlais A, Morin F, Westeel V, Zalcman G. Levallet G, et al. Among authors: dubois f. Oncotarget. 2017 Jan 17;8(3):4313-4329. doi: 10.18632/oncotarget.14025. Oncotarget. 2017. PMID: 28008145 Free PMC article. Clinical Trial.
NDR2 kinase contributes to cell invasion and cytokinesis defects induced by the inactivation of RASSF1A tumor-suppressor gene in lung cancer cells.
Keller M, Dubois F, Teulier S, Martin APJ, Levallet J, Maille E, Brosseau S, Elie N, Hergovich A, Bergot E, Camonis J, Zalcman G, Levallet G. Keller M, et al. Among authors: dubois f. J Exp Clin Cancer Res. 2019 Apr 12;38(1):158. doi: 10.1186/s13046-019-1145-8. J Exp Clin Cancer Res. 2019. PMID: 30979377 Free PMC article.
Cancer and RASSF1A/RASSF1C, the Two Faces of Janus.
Dubois F, Bergot E, Levallet G. Dubois F, et al. Trends Cancer. 2019 Nov;5(11):662-665. doi: 10.1016/j.trecan.2019.10.001. Epub 2019 Oct 28. Trends Cancer. 2019. PMID: 31735284
Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial.
Dubois F, Keller M, Hoflack J, Maille E, Antoine M, Westeel V, Bergot E, Quoix E, Lavolé A, Bigay-Game L, Pujol JL, Langlais A, Morin F, Zalcman G, Levallet G. Dubois F, et al. Cancers (Basel). 2019 Nov 21;11(12):1835. doi: 10.3390/cancers11121835. Cancers (Basel). 2019. PMID: 31766357 Free PMC article.
654 results